| Symbol | ADXN |
|---|---|
| Name | ADDEX THERAPEUTICS LTD. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Pharmaceutical Preparations |
| Address | CHEMIN DES MINES 9, GENEVA, V8 CH-1202 |
| Telephone | 01141228841555 |
| Fax | — |
| — | |
| Website | https://www.addextherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001574232 |
| Description | Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The companys geographical area of operations includes Switzerland and Europe. Additional info from NASDAQ: |
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Read moreAddex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Read moreAddex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreAddex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Read moreAddex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Read moreNew Form 20-F - Addex Therapeutics Ltd. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062447 <b>Size:</b> 17 MB
Read more